 |
| FAQ/Help |
| Calendar |
| Search |
|
#1
Oct 29, 2012, 05:50 AM
|
|||
|
|||
 LONDON/TOKYO (Reuters) - GlaxoSmithKline has raised its bet on a promising drug for HIV/AIDS by redrawing a deal with Japan's Shionogi, giving it a much bigger economic interest in the new product. Dolutegravir, a once-daily drug that has performed strongly in clinical trials, is seen by analysts as a potential multibillion-dollar-a-year seller and a strong competitor to treatments from market leader Gilead Sciences. ...More... From Yahoo Health. |
| Reply |
This is an old thread. You probably should not post your reply to it, as the original poster is unlikely to see it.|
|
My Support Forums is the online community that was originally begun as the Psych Central Forums in 2001. It now runs as an independent self-help support group community for mental health, personality, and psychological issues and is overseen by a group of dedicated, caring volunteers from around the world.
Linear Mode
